Kenneth Maynard, DO
Family Medicine · Lizton, INNPI 1730103730
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.7% of the total across 306 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 31 manufacturers reported payments, led by Novo Nordisk at 24.4% of the total. Reporting peaked in 2022 at $1,076 and has fallen 72.3% since, to $298 in 2025.
Across 306 payments — averaging $16.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$1K
- AbbVie$738
- AstraZeneca$561
- Otsuka America Pharmaceutical, Inc.$370
- Exact Sciences$280
- Lilly USA, LLC$238
- plus $2K from 25 others
Across 216 payments — averaging $5274.28 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$406K
- Pfizer$368K
- Eli Lilly$139K
- AstraZeneca$101K
- Vivus LLC$74K
- Cipla USA Inc.$45K
- plus $6K from 2 others
What the payments were for
- Food & beverage$4,959100%
- Education$140%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 70 | $1,213 |
| AbbVie | 54 | $738 |
| AstraZeneca | 37 | $561 |
| Otsuka America Pharmaceutical, Inc. | 21 | $370 |
| Exact Sciences | 14 | $280 |
| Lilly USA, LLC | 20 | $238 |
| GSK | 11 | $223 |
| Pfizer | 17 | $189 |
| Ironshore Pharmaceuticals Inc. | 8 | $161 |
| Phathom Pharmaceuticals, Inc. | 5 | $150 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $107 |
| Eisai Inc. | 5 | $103 |
| Novartis | 6 | $84 |
| Biohaven Pharmaceuticals, Inc. | 3 | $63 |
| Bayer | 3 | $62 |
| Biohaven Pharmaceutical Holding Company Ltd. | 4 | $61 |
| Daiichi Sankyo Inc. | 3 | $53 |
| Amarin Pharma, Inc. | 2 | $39 |
| Ultragenyx Pharmaceutical Inc. | 2 | $37 |
| Amgen(2 entities) | 2 | $31 |
| Corium, LLC | 1 | $30 |
| Mylan Specialty L.p. | 2 | $30 |
| Kowa Pharmaceuticals America, Inc. | 2 | $27 |
| Paratek Pharmaceuticals, Inc. | 1 | $21 |
| Lundbeck LLC | 1 | $21 |
| Astellas Pharma US Inc | 1 | $17 |
| Dynavax Technologies Corporation | 1 | $15 |
| Antares Pharma, Inc. | 1 | $14 |
| Currax Pharmaceuticals LLC | 1 | $13 |
| E.r. Squibb & Sons, L.L.C. | 1 | $12 |
| Shire North American Group Inc | 1 | $11 |
How this compares
$4,974 in reported general payments places this provider in the 85th percentile of 2,709 family medicine providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 17 | $18,173 |
| TrulicityDulaglutide | 11 | $10,519 |
| Atorvastatin Calcium | 179 | $1,378 |
| Omeprazole | 93 | $1,231 |
| Tamsulosin Hcl | 89 | $1,197 |
| Gabapentin | 62 | $1,143 |
| Levothyroxine Sodium | 122 | $1,067 |
| Famotidine | 51 | $856 |
| Metformin Hcl ErMetformin Hcl | 108 | $845 |
| Ropinirole Hcl | 23 | $788 |
| Amlodipine Besylate | 161 | $723 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 45 | $715 |
| Fenofibrate | 33 | $671 |
| Valsartan | 28 | $656 |
| Bupropion Hcl | 17 | $652 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta | $223 | $18,17317 claims |
| Lilly USA, LLCTrulicity | $238 | $10,51911 claims |
| AbbVieSynthroid | $738 | $29816 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,709 family medicine providers in Indiana.
Other family medicine in Lizton
- Richard TannerIndianapolis$1.6M
- James AndryBloomington$715K
- Richard FeldmanIndianapolis$476K
- Anthony InzerelloEvansville$308K
- Joe BanksIndianapolis$294K
- Steven GatewoodElwood$281K
- Shekar PushpalaCarmel$239K
- Victoria MoyerKokomo$188K
- Thomas KintanarFort Wayne$185K
- Jeffrey HiltzMuncie$177K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.